Bevacizumab, a monoclonal anti-vascular endothelial growth factor (VEGF-A) antibody, is currently the only targeted drug authorized for metastatic BC treatment, but it is ineffective in the treatment of metastatic TNBC subsets [12]. Here, VEGFA is linked to breast cancer.